Intelligence · Clinical Development
Pipeline search results
Programs matching “toripalimab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 27 pipeline programs matching "toripalimab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AFMMUChina
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Small Cell Lung Cancer
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
2 trials -
toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Cancer
1 trial -
STC-15 in combination with toripalimab
Coherus Oncology
Solid Tumor
1 trial -
SYSUCC-CMY-2022-0416
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Locally Advanced Colon Cancer
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Pancreatic Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
Toripalimab
Coherus Oncology
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
1 trial -
Toripalimab
Coherus Oncology
Localized Colon Carcinoma
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tracheal Squamous Cell Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Adenocarcinoma of the Stomach
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Urinary Bladder Neoplasms
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Therapy
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Triple-Negative Breast Cancer (TNBC)
1 trial -
Toripalimab
Yongchang Zhang
Advanced Non Small Cell Lung Cancer
1 trial -
Toripalimab
Coherus Oncology
Sinonasal Cancer
1 trial -
Toripalimab + Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thymic Epithelial Tumor
1 trial -
Toripalimab + Chemotherapy
Coherus Oncology
Head and Neck Cancer
1 trial -
Toripalimab+Nedaplatin+Albumin Paclitaxel
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.